TREATMENT SET TS343825 injection, solution
TREATMENT SET TS343826 injection, solution
TREATMENT SET TS344001 injection, soluti United States - English - NLM (National Library of Medicine)

treatment set ts343825 injection, solution treatment set ts343826 injection, solution treatment set ts344001 injection, soluti

antigen laboratories, inc. - alternaria alternata (unii: 52b29rec7h) (alternaria alternata - unii:52b29rec7h), aspergillus fumigatus (unii: x88df51t48) (aspergillus fumigatus - unii:x88df51t48), cochliobolus sativus (unii: 3ln5b70u4w) (cochliobolus sativus - unii:3ln5b70u4w), cladosporium cladosporioides (unii: 4zwy20gtgo) (cladosporium cladosporioides - unii:4zwy20gtgo), penicillium chrysogenum var. chrysogenum (unii: 3y1pe1gcig) (penicillium chrysogenum var. chrysogenum - unii:3y1pe1gcig) - alternaria alternata 0.01 g in 1 ml - when the natural exposure to elevated aeroallergens produces symptoms as described under clinical pharmacology, specific diagnosis and therapeutic procedures are indicated. clearly, important clues to the cause of a person's allergic condition can be gleaned from a thorough history and careful physical examination. diagnostic tests - in vitro or in vivo - serve only to confirm the physician's suspicions or to improve investigative skills. specific diagnosis is especially indicated when the patient's symptoms are not controlled by medication. when immunotherapy is contemplated demonstration of sensitivity to a specific allergenic extract is necessary. an orderly approach to the use of diagnostic tests usually begins with direct skin testing. 5,6,11 this product is not intended for treatment of patients who do not manifest immediate hypersensitivity reactions to the allergenic extract following skin testing. there are no absolute contraindications; however, extreme caution is necessary when using diagnostic ski

MOLD MIX A- alternaria alternata, aspergillus fumigatus, cladosporium cladosporioides and penicillium chrysogenum var. chrysogen United States - English - NLM (National Library of Medicine)

mold mix a- alternaria alternata, aspergillus fumigatus, cladosporium cladosporioides and penicillium chrysogenum var. chrysogen

alk-abello, inc. - alternaria alternata (unii: 52b29rec7h) (alternaria alternata - unii:52b29rec7h), aspergillus fumigatus (unii: x88df51t48) (aspergillus fumigatus - unii:x88df51t48), cladosporium cladosporioides (unii: 4zwy20gtgo) (cladosporium cladosporioides - unii:4zwy20gtgo), penicillium chrysogenum var. chrysogenum (unii: 3y1pe1gcig) (penicillium chrysogenum var. chrysogenum - unii:3y1pe1gcig) - these products are for diagnostic use only. diagnostic allergenic extracts are indicated for use in skin testing to establish the clinical relevance of specific allergens to which the patient has been exposed. by measuring skin test response, the physician may assess the degree of sensitivity that patients have to the allergens. for extracts standardized in au and bau, see individual directions for use. allergenic extracts for diagnostic use only of coffee, mosquito, cottonseed, and flaxseed have not been shown by adequate data to be safe and effective for therapeutic use. patients on beta blockers can be non-responsive to beta agonists that may be required to reverse a systemic reaction (also, see boxed warning statement and adverse reactions ). the physician should carefully weigh the benefit derived from skin testing vs. the risk to the patient should a systemic reaction arise. patients with unstable asthma or steroid dependent asthmatics and patients with underlying cardiovascular disease are at greater

MOLD MIX A- alternaria alternata, aspergillus fumigatus, cladosporium cladosporioides and penicillium chrysogenum var. chrysogen United States - English - NLM (National Library of Medicine)

mold mix a- alternaria alternata, aspergillus fumigatus, cladosporium cladosporioides and penicillium chrysogenum var. chrysogen

alk-abello, inc. - alternaria alternata (unii: 52b29rec7h) (alternaria alternata - unii:52b29rec7h), aspergillus fumigatus (unii: x88df51t48) (aspergillus fumigatus - unii:x88df51t48), cladosporium cladosporioides (unii: 4zwy20gtgo) (cladosporium cladosporioides - unii:4zwy20gtgo), penicillium chrysogenum var. chrysogenum (unii: 3y1pe1gcig) (penicillium chrysogenum var. chrysogenum - unii:3y1pe1gcig) - hyposensitization (injection) therapy is a treatment for patients exhibiting allergic reactions to seasonal pollens, dust, molds, animal danders, various other inhalants, and in situations where the offending allergen cannot be avoided. prior to initiation of therapy, the clinical sensitivity should be established by careful evaluation of the patient’s history confirmed by diagnostic skin testing. hyposensitization should not be prescribed for sensitivities to allergens which can easily be avoided. a patient should not be immunized with preparations of allergens to which the patient has not demonstrated symptoms, ige antibodies, positive skin tests, or properly controlled challenge testing. in most cases, immunotherapy is not indicated for those allergens that can be eliminated or minimized by environmental control. patients on beta-blockers are not candidates for immunotherapy, as they can be non-responsive to beta-agonists that may be required to reverse a systemic reaction (also see warnings and adverse

MOLD MIX A- alternaria alternata, aspergillus fumigatus, cladosporium cladosporioides and penicillium chrysogenum var. chrysogen United States - English - NLM (National Library of Medicine)

mold mix a- alternaria alternata, aspergillus fumigatus, cladosporium cladosporioides and penicillium chrysogenum var. chrysogen

alk-abello, inc. - alternaria alternata (unii: 52b29rec7h) (alternaria alternata - unii:52b29rec7h), aspergillus fumigatus (unii: x88df51t48) (aspergillus fumigatus - unii:x88df51t48), cladosporium cladosporioides (unii: 4zwy20gtgo) (cladosporium cladosporioides - unii:4zwy20gtgo), penicillium chrysogenum var. chrysogenum (unii: 3y1pe1gcig) (penicillium chrysogenum var. chrysogenum - unii:3y1pe1gcig) - hyposensitization (injection) therapy is a treatment for patients exhibiting allergic reactions to seasonal pollens, dust, molds, animal danders, various other inhalants, and in situations where the offending allergen cannot be avoided. prior to initiation of therapy, the clinical sensitivity should be established by careful evaluation of the patient’s history confirmed by diagnostic skin testing. hyposensitization should not be prescribed for sensitivities to allergens which can easily be avoided. a patient should not be immunized with preparations of allergens to which the patient has not demonstrated symptoms, ige antibodies, positive skin tests, or properly controlled challenge testing. in most cases, immunotherapy is not indicated for those allergens that can be eliminated or minimized by environmental control. patients on beta-blockers are not candidates for immunotherapy, as they can be non-responsive to beta-agonists that may be required to reverse a systemic reaction (also see warnings and adverse

Test Australia - English - Department of Health (Therapeutic Goods Administration)

test

stallergenes australia pty ltd - alternaria alternata, quantity: 0.5 ml (equivalent: alternaria alternata, qty 10 mg/ml); phoma herbarum, quantity: 0.5 ml (equivalent: phoma herbarum, qty 10 mg/ml); cochliobolus heterostrophus, quantity: 0.25 ml (equivalent: cochliobolus heterostrophus, qty 5 mg/ml); aspergillus fumigatus, quantity: 0.1 ml (equivalent: aspergillus fumigatus, qty 3 mg/ml); aspergillus terreus, quantity: 0.1 ml (equivalent: aspergillus terreus, qty 3 mg/ml); aspergillus nidulans, quantity: 0.1 ml (equivalent: aspergillus nid - extract, liquid - excipient ingredients: glycerol; sodium chloride; sodium bicarbonate; water for injections - indicated use of allergenic extracts is for the diagnosis and treatment (hypo-sensitization therapy) of patients who experience allergic symptoms.

Moulds mix 25micrograms/ml solution for skin prick test United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

moulds mix 25micrograms/ml solution for skin prick test

inmunotek - alternaria alternata (a.tenuis) allergen extract; aspergillus fumigatus allergen extract; cladosporium herbarum allergen extract - solution for skin-prick test

SORREL/DOCK MIX- rumex acetosella pollen and rumex crispus pollen injection, solution
MIXED MOLDS- alternaria alternata, asperg United States - English - NLM (National Library of Medicine)

sorrel/dock mix- rumex acetosella pollen and rumex crispus pollen injection, solution mixed molds- alternaria alternata, asperg

alk-abello, inc. - rumex acetosella pollen (unii: n52miq81zw) (rumex acetosella pollen - unii:n52miq81zw), rumex crispus pollen (unii: v825xjg64g) (rumex crispus pollen - unii:v825xjg64g) - alternaria alternata 0.1 g in 1 ml - these products are for diagnostic use only. diagnostic allergenic extracts are indicated for use in skin testing to establish the clinical relevance of specific allergens to which the patient has been exposed. by measuring skin test response, the physician may assess the degree of sensitivity that patients have to the allergens. for extracts standardized in au and bau, see individual directions for use. allergenic extracts for diagnostic use only of coffee, mosquito, cottonseed, and flaxseed have not been shown by adequate data to be safe and effective for therapeutic use. patients on beta blockers can be non-responsive to beta agonists that may be required to reverse a systemic reaction (also, see boxed warning statement and adverse reactions ). the physician should carefully weigh the benefit derived from skin testing vs. the risk to the patient should a systemic reaction arise. patients with unstable asthma or steroid dependent asthmatics and patients with underlying cardiovascular disease are at greater

TREATMENT SET TS344059 injection, solution
TREATMENT SET TS344419 injection, solution
TREATMENT SET TS344420 injection, soluti United States - English - NLM (National Library of Medicine)

treatment set ts344059 injection, solution treatment set ts344419 injection, solution treatment set ts344420 injection, soluti

antigen laboratories, inc. - felis catus hair (unii: 1564hd0n96) (felis catus hair - unii:1564hd0n96), ambrosia artemisiifolia pollen (unii: k20y81aco3) (ambrosia artemisiifolia pollen - unii:k20y81aco3), aspergillus fumigatus (unii: x88df51t48) (aspergillus fumigatus - unii:x88df51t48), alternaria alternata (unii: 52b29rec7h) (alternaria alternata - unii:52b29rec7h) - felis catus hair 2000 [bau] in 1 ml - when the natural exposure to elevated aeroallergens produces symptoms as described under clinical pharmacology, specific diagnosis and therapeutic procedures are indicated. clearly, important clues to the cause of a person's allergic condition can be gleaned from a thorough history and careful physical examination. diagnostic tests - in vitro or in vivo - serve only to confirm the physician's suspicions or to improve investigative skills. specific diagnosis is especially indicated when the patient's symptoms are not controlled by medication. when immunotherapy is contemplated demonstration of sensitivity to a specific allergenic extract is necessary. an orderly approach to the use of diagnostic tests usually begins with direct skin testing. 5,6,11 this product is not intended for treatment of patients who do not manifest immediate hypersensitivity reactions to the allergenic extract following skin testing. there are no absolute contraindications; however, extreme caution is necessary when using diagnostic ski

TREATMENT SET TS335823 injection, solution
TREATMENT SET TS335861 injection, solution United States - English - NLM (National Library of Medicine)

treatment set ts335823 injection, solution treatment set ts335861 injection, solution

antigen laboratories, inc. - poa pratensis pollen (unii: scb8j7ls3t) (poa pratensis pollen - unii:scb8j7ls3t), dermatophagoides farinae (unii: pr9u2ypf3q) (dermatophagoides farinae - unii:pr9u2ypf3q), alternaria alternata (unii: 52b29rec7h) (alternaria alternata - unii:52b29rec7h), ambrosia trifida pollen (unii: ku1v1898xx) (ambrosia trifida pollen - unii:ku1v1898xx), ambrosia artemisiifolia pollen (unii: k20y81aco3) (ambrosia artemisiifolia pollen - unii:k20y81aco3), ambrosia psilostachya pollen (unii: rx18m46k8l) (ambrosia psil - poa pratensis pollen 160 [bau] in 1 ml - when the natural exposure to elevated aeroallergens produces symptoms as described under clinical pharmacology, specific diagnosis and therapeutic procedures are indicated. clearly, important clues to the cause of a person's allergic condition can be gleaned from a thorough history and careful physical examination. diagnostic tests - in vitro or in vivo - serve only to confirm the physician's suspicions or to improve investigative skills. specific diagnosis is especially indicated when the patient's symptoms are not controlled by medication. when immunotherapy is contemplated demonstration of sensitivity to a specific allergenic extract is necessary. an orderly approach to the use of diagnostic tests usually begins with direct skin testing. 5,6,11 this product is not intended for treatment of patients who do not manifest immediate hypersensitivity reactions to the allergenic extract following skin testing. there are no absolute contraindications; however, extreme caution is necessary when using diagnostic ski

TREATMENT SET TS339184 injection, solution
TREATMENT SET TS339185 injection, solution United States - English - NLM (National Library of Medicine)

treatment set ts339184 injection, solution treatment set ts339185 injection, solution

antigen laboratories, inc. - felis catus hair (unii: 1564hd0n96) (felis catus hair - unii:1564hd0n96), alternaria alternata (unii: 52b29rec7h) (alternaria alternata - unii:52b29rec7h), canis lupus familiaris hair (unii: 05s7l91ztr) (canis lupus familiaris hair - unii:05s7l91ztr), periplaneta americana (unii: 2rq1l9n089) (periplaneta americana - unii:2rq1l9n089), aspergillus fumigatus (unii: x88df51t48) (aspergillus fumigatus - unii:x88df51t48), cochliobolus sativus (unii: 3ln5b70u4w) (cochliobolus sativus - unii:3ln5b70u4w), clad - felis catus hair 16 [bau] in 1 ml - when the natural exposure to elevated aeroallergens produces symptoms as described under clinical pharmacology, specific diagnosis and therapeutic procedures are indicated. clearly, important clues to the cause of a person's allergic condition can be gleaned from a thorough history and careful physical examination. diagnostic tests - in vitro or in vivo - serve only to confirm the physician's suspicions or to improve investigative skills. specific diagnosis is especially indicated when the patient's symptoms are not controlled by medication. when immunotherapy is contemplated demonstration of sensitivity to a specific allergenic extract is necessary. an orderly approach to the use of diagnostic tests usually begins with direct skin testing. 5,6,11 this product is not intended for treatment of patients who do not manifest immediate hypersensitivity reactions to the allergenic extract following skin testing. there are no absolute contraindications; however, extreme caution is necessary when using diagnostic ski